{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:48:31Z","timestamp":1781754511239,"version":"3.54.5"},"reference-count":24,"publisher":"Norwegian Medical Association","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.22.0017","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T03:06:22Z","timestamp":1664247982000},"source":"Crossref","is-referenced-by-count":2,"title":["Genotyping of patients treated with selective serotonin reuptake inhibitors"],"prefix":"10.4045","volume":"142","author":[{"given":"Vigdis","family":"Solhaug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Haslemo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne Kristiansen","family":"Kringen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5679-9937","authenticated-orcid":false,"given":"Erik Sveberg","family":"Dietrichs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"ref=1","unstructured":"Nasjonalt reseptbasert legemiddelregister \u2013 Reseptregisteret. http:\/\/www.reseptregisteret.no Lest 12.10.2021."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Peretti\u00a0S, Judge\u00a0R, Hindmarch\u00a0I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000; 101: 17\u201325. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11019931&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fj.1600-0447.2000.tb10944.x","DOI":"10.1111\/j.1600-0447.2000.tb10944.x"},{"key":"ref=3","unstructured":"Norsk legemiddelh\u00e5ndbok. L5.3.1 Selektive serotoninreopptakshemmere. https:\/\/www.legemiddelhandboka.no\/L5.3.1\/Selektive_serotoninreopptakshemmere Lest 12.10.2021."},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Rothmore\u00a0J. Antidepressant-induced sexual dysfunction. Med J Aust 2020; 212: 329\u201334. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32172535&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.5694%2Fmja2.50522","DOI":"10.5694\/mja2.50522"},{"key":"ref=5","unstructured":"U.S. Food & Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related Lest 6.5.2020."},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Lagerberg\u00a0T, Fazel\u00a0S, Sj\u00f6lander\u00a0A et al. Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study. Neuropsychopharmacology 2022; 47: 817\u201323. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34561608&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41386-021-01179-z","DOI":"10.1038\/s41386-021-01179-z"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Juki\u0107\u00a0MM, Haslemo\u00a0T, Molden\u00a0E et al. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. Am J Psychiatry 2018; 175: 463\u201370. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29325448&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1176%2Fappi.ajp.2017.17050550","DOI":"10.1176\/appi.ajp.2017.17050550"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Ren\u00a0F, Ma\u00a0Y, Zhu\u00a0X et al. Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder. J Affect Disord 2020; 273: 254\u201364. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32421611&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jad.2020.04.058","DOI":"10.1016\/j.jad.2020.04.058"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Zhu\u00a0J, Klein-Fedyshin\u00a0M, Stevenson\u00a0JM. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence. Pharmacotherapy 2017; 37: 1089\u2013104. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28654193&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fphar.1978","DOI":"10.1002\/phar.1978"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Stein\u00a0K, Maruf\u00a0AA, M\u00fcller\u00a0DJ et al. Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis. J Pers Med 2021; 11: 1334. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34945806&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3390%2Fjpm11121334","DOI":"10.3390\/jpm11121334"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Ng\u00a0C, Sarris\u00a0J, Singh\u00a0A et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol 2013; 28: 516\u201322. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24014145&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fhup.2340","DOI":"10.1002\/hup.2340"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Porcelli\u00a0S, Fabbri\u00a0C, Serretti\u00a0A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239\u201358. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22137564&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.euroneuro.2011.10.003","DOI":"10.1016\/j.euroneuro.2011.10.003"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Perlis\u00a0RH, Fijal\u00a0B, Dharia\u00a0S et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67: 1110\u20133. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20110084&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.biopsych.2009.12.010","DOI":"10.1016\/j.biopsych.2009.12.010"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Dietrichs\u00a0ES, Smith\u00a0GL. Prediction of Ventricular Arrhythmias by QRS\/QTc - Ratio in Citalopram or Escitalopram Intoxication. Front Med (Lausanne) 2022; 9: 866454. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35372426&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffmed.2022.866454","DOI":"10.3389\/fmed.2022.866454"},{"key":"ref=15","unstructured":"European Medicines Agency. Pharmacovigilance Working Party. (PhVWP) November 2011 plenary meeting. https:\/\/www.ema.europa.eu\/en\/documents\/report\/monthly-report-pharmacovigilance-working-party-phvwp-november-2011-plenary-meeting_en.pdf Lest 20.4.2022."},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Qirjazi\u00a0E, McArthur\u00a0E, Nash\u00a0DM et al. Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study. PLoS One 2016; 11: e0160768. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27513855&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1371%2Fjournal.pone.0160768","DOI":"10.1371\/journal.pone.0160768"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Rudberg\u00a0I, Mohebi\u00a0B, Hermann\u00a0M et al. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008; 83: 322\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17625515&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fsj.clpt.6100291","DOI":"10.1038\/sj.clpt.6100291"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Rosenberg\u00a0KP, Bleiberg\u00a0KL, Koscis\u00a0J et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003; 29: 289\u201396. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14504017&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F00926230390195524","DOI":"10.1080\/00926230390195524"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Atmaca\u00a0M. Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction: Current Management Perspectives. Neuropsychiatr Dis Treat 2020; 16: 1043\u201350. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32368066&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.2147%2FNDT.S185757","DOI":"10.2147\/NDT.S185757"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Hermann\u00a0M, Waade\u00a0RB, Molden\u00a0E. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. Ther Drug Monit 2015; 37: 546\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25565671&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FFTD.0000000000000169","DOI":"10.1097\/FTD.0000000000000169"},{"key":"ref=21","unstructured":"Pharm GKB. https:\/\/www.pharmgkb.org\/ Lest 20.4.2022."},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Odgerel\u00a0Z, Talati\u00a0A, Hamilton\u00a0SP et al. Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health's Collaborative Center for Genomic Studies. Transl Psychiatry 2013; 3: e307. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24064711&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Ftp.2013.80","DOI":"10.1038\/tp.2013.80"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Koopmans\u00a0AB, Braakman\u00a0MH, Vinkers\u00a0DJ et al. Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19. Transl Psychiatry 2021; 11: 141. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33627619&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41398-020-01129-1","DOI":"10.1038\/s41398-020-01129-1"},{"key":"ref=24","unstructured":"Solvik IK. Legemiddelrelaterte innleggingar avdekka i akuttmottak. Masteroppgave. Oslo: Farmas\u00f8ytisk institutt, Universitetet i Oslo, 2018."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Genotyping av pasienter behandlet med selektive serotoninre=opptakshemmere"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:36:07Z","timestamp":1781685367000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2022\/09\/originalartikkel\/genotyping-av-pasienter-behandlet-med-selektive-serotoninreopptakshemmere"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":24,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.22.0017","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}